Humacyte Inc [NASDAQ: HUMA] traded at a high on Thursday, posting a 5.32 gain after which it closed the day’ session at $2.77.
The results of the trading session contributed to over 6565327 shares changing hands. Over the past one week, the price volatility of Humacyte Inc stands at 3.73% while the volatility over the past one month is 8.36%.
The market cap for HUMA stock reached $429.68 million, with 155.12 million shares outstanding and 125.75 million shares in the current float. Compared to the average trading volume of 4.55M shares, HUMA reached a trading volume of 6565327 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Humacyte Inc [HUMA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $9.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 14, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $15. The new note on the price target was released on December 20, 2024, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on HUMA stock. On August 14, 2023, analysts increased their price target for HUMA shares from 2.75 to 3.50.
The Average True Range (ATR) for Humacyte Inc is set at 0.24, with the Price to Sales ratio for HUMA stock in the period of the last 12 months amounting to 826.30. The Price to Book ratio for the last quarter was 11.92, with the Price to Cash per share for the same quarter was set at 0.41.
How has HUMA stock performed recently?
Humacyte Inc [HUMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.38. With this latest performance, HUMA shares gained by 93.71% in over the last four-week period, additionally sinking by -38.31% over the last 6 months – not to mention a drop of -61.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HUMA stock in for the last two-week period is set at 74.27, with the RSI for the last a single of trading hit 81.48, and the three-weeks RSI is set at 66.26 for Humacyte Inc [HUMA]. The present Moving Average for the last 50 days of trading for this stock 1.84, while it was recorded at 2.56 for the last single week of trading, and 4.08 for the last 200 days.
Humacyte Inc [HUMA]: Deeper insight into the fundamentals
Humacyte Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.28 and a Current Ratio set at 3.68.
Insider trade positions for Humacyte Inc [HUMA]
The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
